FDA: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products - Draft

11.12.2014

This draft guidance is intended to assist those sponsors of new drug applications (NDAs), biologics license applications (BLAs) for therapeutic biologics, and supplements to such applications who are planning to conduct clinical studies in pediatric populations.